HYB:NYE-New America High Income Fund Inc. (The) (USD)

ETF | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 7.07

Change

+0.06 (+0.86)%

Market Cap

USD 0.21B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

To provide high current income while preserving capital through investment in diversified portfolio of high-yield fixed-income securities rated in the lower categories by established rating agencies. The portfolio consists primarily of fixed-income securities rated BB / Ba or lower. It has a leveraged capital structure.

Inception Date: 26/02/1988

Primary Benchmark: Credit Suisse HY USD

Primary Index: BBgBarc US Agg Bond TR USD

Gross Expense Ratio: 1.63%

Management Expense Ratio:

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Mer Price(Change) Market Cap
BDX Becton Dickinson and Company 0.00 %

+0.57 (+0.24%)

USD 68.37B
ALC Alcon AG 0.00 %

+0.56 (+0.70%)

USD 39.66B
RMD ResMed Inc 0.00 %

-0.78 (-0.36%)

USD 27.76B
WST West Pharmaceutical Services I.. 0.00 %

+1.81 (+0.49%)

USD 27.24B
BAX Baxter International Inc 0.00 %

-0.39 (-1.07%)

USD 18.60B
TFX Teleflex Incorporated 0.00 %

+0.56 (+0.28%)

USD 10.10B
ATR AptarGroup Inc 0.00 %

+0.68 (+0.46%)

USD 9.88B
STVN Stevanato Group SpA 0.00 %

+0.97 (+3.64%)

USD 7.29B
BLCO Bausch + Lomb Corp 0.00 %

+0.46 (+3.19%)

USD 5.08B
HAE Haemonetics Corporation 0.00 %

-0.18 (-0.19%)

USD 4.30B

ETFs Containing HYB

HYDD 0.00 % 0.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.43% 50% F 46% F
Dividend Return 1.70% 88% B+ 72% C
Total Return 2.13% 61% D- 50% F
Trailing 12 Months  
Capital Gain 5.52% 72% C 53% F
Dividend Return 6.08% 100% F 78% C+
Total Return 11.60% 83% B 57% F
Trailing 5 Years  
Capital Gain -18.36% 27% F 28% F
Dividend Return 29.09% 100% F 85% B
Total Return 10.73% 45% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain -2.70% 22% F 28% F
Dividend Return 3.84% 39% F 46% F
Total Return 6.54% 100% F 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 30.61% 56% F 36% F
Risk Adjusted Return 12.53% 33% F 36% F
Market Capitalization 0.21B 89% A- 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.